Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Apr 2020 10:06 AM
RNS
Director Dealing
27 Apr 2020 04:39 PM
RNS
Director Dealing
24 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
24 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
24 Apr 2020 07:00 AM
RNS
Scancell: Development of vaccine against COVID-19
16 Mar 2020 04:42 PM
RNS
Second Price Monitoring Extn
16 Mar 2020 04:38 PM
RNS
Price Monitoring Extension
03 Mar 2020 07:00 AM
RNS
Scancell to Present at Three Research Conferences
03 Feb 2020 07:00 AM
RNS
SCIB1 IND Application Approved
31 Jan 2020 07:00 AM
RNS
Interim Results
20 Jan 2020 07:00 AM
RNS
Third agreement signed for antibody platform
17 Dec 2019 12:44 PM
RNS
Director's Dealings
16 Dec 2019 07:00 AM
RNS
Second agreement signed for AvidiMab platform
20 Nov 2019 07:00 AM
RNS
New European Moditope patent allowed for grant
23 Oct 2019 07:00 AM
RNS
Directorate Change
26 Sep 2019 07:00 AM
RNS
Posters at Cancer Immunotherapy Conference
12 Sep 2019 03:56 PM
RNS
Result of AGM
04 Sep 2019 07:00 AM
RNS
First Collaboration Agreement for AvidiMab
20 Aug 2019 02:23 PM
RNS
Notice of AGM
20 Aug 2019 07:00 AM
RNS
Final Results for the year ended 30 April 2019
19 Aug 2019 07:00 AM
RNS
Update on the SCIB1 Phase 2 clinical trial
07 Aug 2019 07:00 AM
RNS
Notice of Final Results
01 Jul 2019 07:00 AM
RNS
H1 2019 Business Update
18 Jun 2019 09:16 AM
RNS
Holding(s) in Company
18 Jun 2019 07:00 AM
RNS
Board Appointment
17 Jun 2019 10:45 AM
RNS
Holding(s) in Company
14 Jun 2019 04:41 PM
RNS
Second Price Monitoring Extn
14 Jun 2019 04:35 PM
RNS
Price Monitoring Extension
13 Jun 2019 07:00 AM
RNS
Share Subscription and Issue of Equity to Vulpes
29 May 2019 11:05 AM
RNS
Second Price Monitoring Extn
29 May 2019 11:00 AM
RNS
Price Monitoring Extension
20 May 2019 07:00 AM
RNS
Scancell and CRUK provide an update on SCIB2
10 May 2019 07:00 AM
RNS
Clinical Advisory Board and Update on Modi-1
25 Apr 2019 07:00 AM
RNS
UK approval to start SCIB1 Phase 2 trial
08 Apr 2019 07:00 AM
RNS
Japan patent for Moditope immunotherapy platform
21 Mar 2019 07:00 AM
RNS
Professor Lindy Durrant receives Waldenström award
20 Mar 2019 07:00 AM
RNS
Scancell strengthens IP portfolio
05 Mar 2019 06:27 PM
RNS
Holding(s) in Company
04 Mar 2019 04:40 PM
RNS
Second Price Monitoring Extn
04 Mar 2019 04:35 PM
RNS
Price Monitoring Extension
21 Feb 2019 07:00 AM
RNS
Change of Auditor
31 Jan 2019 07:00 AM
RNS
Interim Results
23 Jan 2019 07:00 AM
RNS
Update on Cancer Research UK's Grand Challenge
21 Jan 2019 07:00 AM
RNS
Appoints Heads of Research and Manufacturing
12 Nov 2018 07:00 AM
RNS
Scancell to Present at Two Conferences
01 Nov 2018 07:00 AM
RNS
Scancell to present at Proactive Investors Forum
30 Oct 2018 05:18 PM
RNS
Results of AGM
30 Oct 2018 07:00 AM
RNS
Identification of 2nd Moditope Cancer Vaccine
24 Oct 2018 09:05 AM
RNS
Second Price Monitoring Extn
24 Oct 2018 09:00 AM
RNS
Price Monitoring Extension

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings